Advertisement

Opioids and Substance Abuse

  • Matthew Verne Satterly
  • Magdalena Anitescu

Abstract

Opioids are a class of medications that have been associated with potent analgesia. Used for thousands of years as effective agents to treat malignant and nonmalignant pain, opioids evolved from simple extracts and alkaloids to potent synthetic formulations employed to treat acute and chronic pain. With extending their role into treating the chronic pain syndromes, controversies arise on the proper indications of those agents questioning the balance between effective pain treatments and the liability for abuse. This chapter will explore the use of opioids and their potential for abuse as well as regulatory mechanisms to limit liability of their use.

Keywords

Opioid analgesia Opioid mechanism of action Opioid abuse Illicit use of opioid Analgesics Opioid regulation Risk factors for opioid abuse Abuse deterrent formulations 

References

  1. 1.
    Corbett AD, Henderson HG, McKnight AT, et al. 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol. 2006;146:S152–62.Google Scholar
  2. 2.
    Mogil JS, Grisel JE. Transgenic studies of pain. Pain. 1998;77:107–28.PubMedCrossRefGoogle Scholar
  3. 3.
    McDonald J, Lambert DG. Opioid receptors. Contin Educ Anaesth Crit Care Pain. 2005;5(1):22–5.CrossRefGoogle Scholar
  4. 4.
    Zacny J, Bigelow G, Comptom P, et al. College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend. 2003;69:215–32.PubMedCrossRefGoogle Scholar
  5. 5.
    Weissman DE, Haddox JD. Opioid pseudoaddiction—an iatrogenic syndrome. Pain. 1989;36(3):363–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Campbell J. MD Presidential Address, American Pain Society November 11, 1996. http://www.va.gov/;ainmangement/doc/toolkit.pdf. Accessed 26 July 2013.
  7. 7.
    Paulozzi LJ, et al. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. Morb Mortal Wkly Rep. 2011;60(43):1487–92.Google Scholar
  8. 8.
    Manchikanti L, Abdil S, Alturi S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part I—evidence assessment. Pain Physician. 2012;15(3 Suppl):S1–65.PubMedGoogle Scholar
  9. 9.
    Grattan A, Sullivan MD, Saunders KW, et al. Depression and prescription opioid misuse among chronic opioid therapy recipients with no history of substance abuse. Ann Fam Med. 2012;10(4):304–11.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
  11. 11.
    Substance Abuse and Mental Health Services Administration. Results from the 2011 national survey on drug use and health: summary of national findings. NSDUH Series H-44, HHS Publication No. (SMA) 12-4713. Rockville: Substance Abuse and Mental Health Services Administration; 2012.Google Scholar
  12. 12.
    Substance Abuse and Mental Health Services Administration. Office of applied studies: treatment episode data set (TEDS). http://wwwdasis.samhsa.gov/webt/NewMapv1.htm
  13. 13.
    Cleland et al. Substance abuse treatment, prevention, and policy 2011, 6:11. http://www.substanceabusepolicy.com/content/6/1/11. Accessed 26 July 2013.
  14. 14.
    Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH. Abuse risks and routes of administration of different prescription opioid compounts and formulations. Harm Reduct J. 2011;8.Google Scholar
  15. 15.
    Swedlow A, Ireland J, Johnson G. Prescribing patterns of schedule II opioids in California workers’ compensation. California Workers Compensation Institute. www.cwci.org. Accessed 25 June 2013.
  16. 16.
    Birnbaum HG, White AG, Schiller M, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12:656–67.CrossRefGoogle Scholar
  17. 17.
    Coalition Against Insurance Fraud. Prescription for peril: how insurance fraud finances theft and abuse of addictive prescription drugs. Washington, DC: Coalition Against Insurance Fraud; 2007. http://www.insurancefraud.org/downloads/drugDiversion.pdf. Accessed 26 Sept 2011.
  18. 18.
    Prescription drugs: abuse and addiction. NIH Publication Number 11-4881. July 2001, Revised October 2011. www.drugabuse.gov/sites/default/files/rrprescription.pdf. Accessed 26 July 2013.
  19. 19.
    Substance Abuse and Mental Health Services Administration. Highlights of the 2009 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits. The DAWN Report. Rockville: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration; 2010. http://oas.samhsa.gov/2k10/dawn034/edhighlights. Accessed 3 Oct 2011.
  20. 20.
    Alexander GA, Kruszewski SP, Webster DW. Rethinking opioid prescribing to protect patient safety and public health. J Am Med Assoc. 2012;308(18):1865–6.CrossRefGoogle Scholar
  21. 21.
    Centers for Disease Control and Prevention. CDC grand rounds: prescription drug overdoses—a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012;61(39):10–3.Google Scholar
  22. 22.
    Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152:85–92.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009;18:1166–75.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic non-cancer pain. Cochrane Database Syst Rev. 2010;(1):CD006605.Google Scholar
  25. 25.
    Seghal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician. 2012;15:ES67–92.Google Scholar
  26. 26.
    Rigg KK, Murphy JW. Understanding the etiology of prescription opioid abuse: implications for prevention and treatment. Qual Health Res. 2013;23(7):963–75.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Boscarino JA, Rukstalis M, Hoffman SN, et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction. 2010;105:1776–82.PubMedCrossRefGoogle Scholar
  28. 28.
    Edlund MJ, Martin BC, Fan M, et al. Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study. Drug Alcohol Depend. 2010;112:90–8.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Grattan A, Sullivan MD, Saunders KW, et al. Depression and prescription opioid misuse among chronic opioid therapy recipients with no history of substance abuse. Ann Fam Med. 2012;10(4):304–11.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Spiller H, Lorenz DL, Bailet EJ, et al. Epidemiological trends in abuse and misuse of prescription opioids. J Addict Dis. 2009;28:130–13.PubMedCrossRefGoogle Scholar
  31. 31.
    Brownstein JS, Green TC, Cassidy TA, et al. Geographic information systems and pharmacoepidemiology: using spatial cluster detection to monitor local patterns of prescription opioid abuse. Pharmacoepidemiol Drug Saf. 2010;19:627–37.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Cicero TJ, Surratt HL, Kurtz S, et al. Patterns of prescription opioid abuse and comorbidity in an aging treatment population. J Subst Abuse Treat. 2013;42:87–94.CrossRefGoogle Scholar
  33. 33.
    Katz C, El-Gabalawy E, Keyes KN, et al. Risk factors for incident nonmedical prescription opioid use and abuse and dependence: results from a longitudinal nationally representative sample. Drug Alcohol Depend. 2013;132.Google Scholar
  34. 34.
    Manubay JM, Muchow C, Sullivan MA. Prescription drug abuse: epidemiology, regulatory issues, chronic pain management with narcotic analgesics. Prim Care. 2011;38(1):71.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Schneider JP, Matthews M, Jamison R. Abuse-deterrent and tamper-resistant opioid formulations—what is their role in addressing prescription opioid abuse? CNS Drugs. 2010;24(10):805–10.PubMedCrossRefGoogle Scholar
  36. 36.
    U.S. Food and Drug Administration. Risk evaluation and mitigation strategies for certain opioid drugs; notice of public hearing. April 20, 2009. http://www.fda.gov/OHRMS/DOCKETS/98fr/E9-8992.pdf

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Anesthesiology, Center for Advanced Medicine, Western Anesthesia Associates, Pain Management CenterWashington University School of MedicineSt. LouisUSA
  2. 2.Department of Anesthesia and Critical CareUniversity of Chicago Medical CenterChicagoUSA

Personalised recommendations